Results for “”

Entry Author Date Location
Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More 02/21/20 National
Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test 02/18/20 San Francisco
Agile Therapeutics Wins FDA Nod for Twirla Contraceptive Patch 02/14/20 New York
Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More 02/14/20 National
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks 02/13/20 National
Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. 02/11/20 National
Biohaven Drug Fails Anxiety Study, Data in OCD and More Still to Come 02/10/20 New York
Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s 02/10/20 National
Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More 02/07/20 National
Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff 02/05/20 New York
Bristol-Myers, BioMotiv Pact Leads to a New Fibrosis-Focused Startup 02/04/20 New York
Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic 02/03/20 New York
Insmed Drug for Rare Pulmonary Disorder Meets Phase 2 Goals 02/03/20 New York
Discovery Labs Converts ex-GSK King of Prussia Site into R&D “Colony” 02/03/20 New York
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy 01/31/20 San Francisco
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More 01/31/20 National
BIO Report: More Work Needed to Improve Diversity at Biotech Firms 01/30/20 National
Annovis Bio Gets $12M in IPO to Target Trio of Neurotoxic Proteins 01/29/20 New York
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus 01/29/20 Boston
Histogen, Timber Pharma Plan Reverse Mergers to Join Public Markets 01/28/20 San Diego
Third Time’s the Charm as Acceleron Drug Shows Early Promise in PAH 01/28/20 Boston
BioIntelliSense Debuts “Sticker” Sensor to Capture Patient Data Remotely 01/28/20 Boulder/Denver
Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report 01/28/20 National
Life Sciences IPOs Target Collective Raise of More Than $600M This Week 01/27/20 National
Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More 01/24/20 National
After AstraZeneca, Osbourn Reflects on Roles at CAT & MedImmune 01/23/20 National
Emendo Eyes the Clinic for CRISPR Therapy That Makes Single-Gene Edits 01/22/20 New York
Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More 01/17/20 National
Emendo Biotherapeutics Nabs $61M for “Next-Generation CRISPR” R&D 01/15/20 New York
FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data 01/14/20 National
Page 1 of 151 next page »